Equities Analysts Set Expectations for FDMT FY2024 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of 4D Molecular Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($2.95) for the year, down from their prior forecast of ($2.84). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.81) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics' Q4 2024 earnings at ($0.86) EPS and FY2025 earnings at ($3.76) EPS.

A number of other brokerages have also recently weighed in on FDMT. Chardan Capital reissued a "buy" rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday. Leerink Partners reaffirmed an "outperform" rating and issued a $36.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, September 23rd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $47.00.

4D Molecular Therapeutics Stock Down 5.8 %

Shares of FDMT traded down $0.51 during mid-day trading on Monday, reaching $8.32. 1,909,091 shares of the company's stock were exchanged, compared to its average volume of 897,701. The company has a 50-day simple moving average of $10.30 and a two-hundred day simple moving average of $17.03. 4D Molecular Therapeutics has a 52-week low of $7.32 and a 52-week high of $36.25. The company has a market cap of $384.63 million, a price-to-earnings ratio of -3.10 and a beta of 2.82.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors have recently made changes to their positions in the stock. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of 4D Molecular Therapeutics by 10.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company's stock valued at $14,819,000 after buying an additional 65,000 shares during the period. Kennedy Capital Management LLC acquired a new stake in 4D Molecular Therapeutics in the 1st quarter valued at $4,358,000. Sofinnova Investments Inc. raised its position in 4D Molecular Therapeutics by 36.8% in the second quarter. Sofinnova Investments Inc. now owns 271,155 shares of the company's stock valued at $5,692,000 after purchasing an additional 72,969 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of 4D Molecular Therapeutics by 702.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company's stock worth $110,000 after purchasing an additional 3,026 shares in the last quarter. Finally, Novo Holdings A S boosted its position in shares of 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company's stock worth $16,215,000 after buying an additional 100,000 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.